Abdul-Rahman Jazieh Department of Oncology (Mail code 1777) P.O. Box 22490, Riyadh 11426 Saudi Arabia
Source of Support: None, Conflict of Interest: None
The systemic treatment of lung cancer has evolved rapidly over the last two decades. Systemic therapy has become the standard of care for advanced lung cancer up to the third line.
The addition of antiangiogenesis agents to chemotherapy has proved to be beneficial in the first-line setting. Finally, systemic therapy has proven effective in the adjuvant setting in early-stage lung cancer.